Cogent Biosciences (COGT) EBIT Margin (2017 - 2020)
Cogent Biosciences (COGT) posted quarterly EBIT Margin of 18333.01% for Q3 2020, down 1715301.0% year-over-year from N/an in Q4 2019, and down 1207.56% quarter-over-quarter from 1402.08% in Q2 2020.
Analysis
Cogent Biosciences (COGT) EBIT Margin (2017 - 2020) Analysis & Trends
Cogent Biosciences (COGT) has reported EBIT Margin for 4 consecutive years, with 18333.01% the latest figure, recorded in Q3 2020.
- In Q3 2020, EBIT Margin fell 1715301.0% year-over-year to 18333.01%; the TTM figure through Dec 2020 stood at 1044.33% (down 90131.0% YoY), while the FY2020 annual figure was 1044.33%, down 90131.0% from the prior year.
- EBIT Margin retreated to 18333.01% in Q3 2020 per COGT's latest filing, from 1402.08% in the prior quarter.
- Across five years, EBIT Margin topped out at 14.65% in Q4 2019 and bottomed at 18333.01% in Q3 2020.
- Historically, EBIT Margin has averaged 1640.08% across 4 years, with a median of 332.18% in 2017.
- On a YoY basis, EBIT Margin climbed as much as 30051 bps in 2020 and fell as far as 1715301 bps in 2020.
- Cogent Biosciences' EBIT Margin stood at 324.07% in 2017, then rose by 27 bps to 236.64% in 2018, then soared by 106 bps to 14.65% in 2019, then plunged by 125223 bps to 18333.01% in 2020.
- Business Quant data shows COGT's EBIT Margin at 18333.01% in Q3 2020, 1402.08% in Q2 2020, and 87.34% in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | Cogent Biosciences | 5.93 Bn | 5.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | -18,333.01% |
| Jun 30, 2020 | -1,402.08% |
| Mar 31, 2020 | -87.34% |
| Dec 31, 2019 | 14.65% |
| Sep 30, 2019 | -1,180.00% |
| Jun 30, 2019 | -335.91% |
| Mar 31, 2019 | -387.85% |
| Dec 31, 2018 | -236.64% |
| Sep 30, 2018 | -517.67% |
| Jun 30, 2018 | -566.57% |
| Mar 31, 2018 | -314.68% |
| Dec 31, 2017 | -324.07% |
| Sep 30, 2017 | -307.59% |
| Jun 30, 2017 | -290.19% |
| Mar 31, 2017 | -332.18% |